Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Annexon (Nasdaq: ANNX) announced inducement equity awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on January 9, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4). In aggregate the hires received options to purchase 155,000 shares of common stock. The options have a 10-year term, an exercise price of $6.16 per share (the closing price on January 15, 2026, the grant date), and vest over 4 years with 25% vesting at the first anniversary and the remainder vesting monthly thereafter, subject to continued service.
Positive
- None.
Negative
- None.
News Market Reaction – ANNX
In the Jan 20 session, ANNX gained 1.48%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Platform milestones | Positive | +5.9% | Outlined 2026 priorities and multiple registrational milestones with cash runway guidance. |
| Jan 08 | Regulatory submission | Positive | -4.3% | Filed MAA with EMA for tanruprubart in GBS with supporting Phase 3 data. |
| Jan 07 | Conference presentation | Neutral | +8.4% | Announced presentation slot at J.P. Morgan Healthcare Conference with webcast access. |
| Dec 16 | Inducement grant | Neutral | +2.1% | Granted a 19,000‑share stock option inducement with standard four‑year vesting. |
| Nov 14 | Equity offering | Negative | +11.4% | Closed underwritten public offering of shares and pre‑funded warrants for $86.25M. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed alignment, with both positive and dilutive events sometimes moving shares contrary to their apparent tone.
Over recent months, Annexon has reported several material milestones. On Nov 14, 2025, it closed a public offering with gross proceeds of $86.25M. A prior 424B5 detailed a primary offering of 25,096,153 shares plus 3,750,000 pre‑funded warrants at $2.60 per share. In December 2025, it granted a 19,000‑share inducement option. Early January 2026 brought an MAA submission for tanruprubart in GBS and a broader 2026 strategy update with multiple registrational milestones. Today’s additional inducement grants fit within this ongoing capital formation and hiring cadence.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the new non-executive employees received options to purchase 155,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
